Dinesh Khanna

University of Michigan–Ann Arbor — United States

Medicine · Health Sciences

101h-index56.0kcitations815works8.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Systemic Sclerosis and Related Diseases(591), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis(266), Inflammatory Myopathies and Dermatomyositis(131), Dermatologic Treatments and Research(130), Mast cells and histamine(103)

Publications803 total

Multimodal analyses of early, untreated systemic sclerosis skin identify a proinflammatory vascular niche of macrophage-fibroblast signaling
JCI Insight·2025Open Access
Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis–Related Interstitial Lung Disease (Scleroderma Lung Study <scp>III</scp> ): An Investigator‐Initiated, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Phase 2 Trial
ACR Open Rheumatology·2025Open Access
Prospective SARS-CoV-2 additional vaccination in immunosuppressant-treated individuals with autoimmune diseases in a randomized controlled trial
JCI Insight·2025Open Access
207 Brentuximab vedotin treatment reduces inflammatory gene expression by T and B cells in scleroderma skin, leading to reduced expression of pro-fibrotic markers
Journal of Investigative Dermatology·2025
<scp>PPISHES</scp> —an enhanced physicochemical approach for predicting protein interaction sites using graph neural networks
Protein Science·2025Open Access
Risk factors for interstitial lung disease in early rheumatoid arthritis and external validation of screening strategies: a cross-sectional analysis of the prospective SAIL-RA cohort in the USA
The Lancet Rheumatology·2025· 7 citedOpen Access
Morphological reprogramming of primary cilia length mitigates the fibrotic phenotype in fibroblasts across diverse fibrotic conditions
Journal of Cell Science·2025· 2 cited
How do doctors and patients communicate about the treatment of systemic sclerosis-associated interstitial lung disease? A plain language summary of publication
Therapeutic Advances in Respiratory Disease·2025Open Access
LB1182 Multi-ancestry genome-wide association meta-analysis identifies novel systemic sclerosis loci and elucidates cell-type specific regulatory mechanisms
Journal of Investigative Dermatology·2025Open Access
0093 Comparative analysis of single-cell and spatial data from multiple fibrotic skin conditions
Journal of Investigative Dermatology·2025Open Access
0920 Stromal NNMT links metabolic and epigenetic drivers of fibrosis in systemic sclerosis
Journal of Investigative Dermatology·2025
0538 Exploring the role of m6A-RNA methylation in severe epidermolysis bullosa simplex
Journal of Investigative Dermatology·2025Open Access
Patient-reported outcomes in systemic sclerosis: insights into quality of life and disease burden
Current Opinion in Rheumatology·2025
Cognitive debriefing of the Scleroderma Health Assessment Questionnaire in diffuse cutaneous systemic sclerosis
Journal of Scleroderma and Related Disorders·2025Open Access
POS0656 TOLERABILITY AND EFFICACY OF BMS-986353 (CC-97540), A CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY MANUFACTURED USING A NEXT-GENERATION PROCESS FOR SYSTEMIC SCLEROSIS: UPDATED DATA FROM THE PHASE 1 BREAKFREE-1 STUDY
Annals of the Rheumatic Diseases·2025· 2 citedOpen Access
Author Reply to Peer Reviews of Morphological Reprogramming of Primary Cilia Length Mitigates the Fibrotic Phenotype in fibroblasts across diverse fibrotic conditions
2025
Hand Swelling and Other Non–Raynaud Phenomenon Symptoms as the Initial Presentation of Systemic Sclerosis: Prevalence and Clinical Associations in Two <scp>US</scp> Cohorts
Arthritis & Rheumatology·2025· 1 citedOpen Access
Predicting the risk of subsequent progression in patients with systemic sclerosis-associated interstitial lung disease with progression: a multicentre observational cohort study
The Lancet Rheumatology·2025· 13 cited
Use of Nintedanib for the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States
Annals of the American Thoracic Society·2025
Serum type I interferon score as a disease activity biomarker in patients with diffuse cutaneous systemic sclerosis: a retrospective cohort study
The Lancet Rheumatology·2025· 9 cited
page 1 of 41Next →

Frequent Co-authors

Daniel E. Furst(21), Christopher P. Denton(15), Virginia Steen(12), Maureen D. Mayes(11), Oliver Distler(10), Yannick Allanore(10), James R. Seibold(10), Leland W.K. Chung(10), Robert W. Simms(9), Janet Pope(9), Marco Matucci‐Cerinic(8), Philip J. Clements(8), Jacob M. van Laar(8), Vivien Hsu(8), Richard M. Silver(8), Sindhu R. Johnson(7), Gabriela Riemekasten(7), Ulf Müller‐Ladner(7), Murray Baron(6), Thomas A. Medsger(6)